Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis

Cancer Immunology, Immunotherapy

Volumn 65, Issue 8, 2016, Pages 951-959

  Heppt, Markus V ^a   Eigentler, Thomas K ^b   Kähler, Katharina C ^c   Herbst, Rudolf A ^d   Göppner, Daniela ^e   Gambichler, Thilo ^f   Ulrich, Jens ^g   Dippel, Edgar ^h   Loquai, Carmen ⁱ   Schell, Beatrice ^j   Schilling, Bastian ^k,l   Schäd, Susanne G ^m   Schultz, Erwin S ⁿ   Matheis, Fanny ^a   Tietze, Julia K ^a   Berking, Carola ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d HELIOS KLINIKUM ERFURT   (Germany)

^e OTTO VON GUERICKE UNIVERSITY   (Germany)

^f RUHR UNIVERSITY BOCHUM   (Germany)

^g Klinikum Dorothea Christiane Erxleben Quedlinburg gGmbH   (Germany)

^h Clinical Center of Ludwigshafen   (Germany)

ⁱ UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^j SRH Wald Klinikum Gera   (Germany)

^k UNIVERSITY OF DUISBURG ESSEN   (Germany)

^l GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^m UNIVERSITY MEDICAL CENTER ROSTOCK   (Germany)

ⁿ PARACELSUS MEDICAL UNIVERSITY   (Germany)

more..

Author keywords

Electrochemotherapy; Immune checkpoint blockade; Ipilimumab; Melanoma; Nivolumab; Pembrolizumab

Indexed keywords

BLEOMYCIN; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; ASCITES; AUTOIMMUNE DISEASE; BLEEDING; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; COLITIS; DIARRHEA; DISTANT METASTASIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; ELECTROCHEMOTHERAPY; ERYTHEMA; FATIGUE; FEASIBILITY STUDY; FEMALE; FEVER; HUMAN; HYPERKALEMIA; HYPERTHYROIDISM; HYPERTRANSAMINASEMIA; HYPOPHYSITIS; INFECTION; INSOMNIA; LEUKOCYTOSIS; LOSS OF APPETITE; MALE; METASTATIC MELANOMA; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA; NECROSIS; NEEDLE ELECTRODE; OVERALL SURVIVAL; PAIN; PERITONITIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; PULSE GENERATOR; RASH; RETROSPECTIVE STUDY; SEPSIS; SKIN METASTASIS; TREATMENT RESPONSE; CELL CYCLE CHECKPOINT; CLINICAL TRIAL; IMMUNOLOGY; MELANOMA; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CELL CYCLE CHECKPOINTS; ELECTROCHEMOTHERAPY; HUMANS; MELANOMA; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84974777729     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-016-1856-z     Document Type: Article

References (25)

1. Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723. doi:10.1056/NEJMoa1003466
2. Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517–2526. doi:10.1056/NEJMoa1104621
3. Schadendorf D, Hodi FS, Robert C et al (2015) Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33(17):1889–1894. doi:10.1200/JCO.2014.56.2736
4. Ribas A, Puzanov I, Dummer R et al (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16(8):908–918. doi:10.1016/S1470-2045(15)00083-2
5. Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372(26):2521–2532. doi:10.1056/NEJMoa1503093
6. Larkin J, Lao CD, Urba WJ, McDermott DF, Horak C, Jiang J, Wolchok JD (2015) Efficacy and safety of nivolumab in patients with BRAF V600 mutant and braf wild-type advanced melanoma: a pooled analysis of 4 clinical trials. JAMA Oncol 1(4):433–440. doi:10.1001/jamaoncol.2015.1184
7. Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320–330. doi:10.1056/NEJMoa1412082
8. Weber JS, D’Angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16(4):375–384. doi:10.1016/S1470-2045(15)70076-8
9. Thallinger C, Prager G, Ringl H, Zielinski C (2015) Abscopal effect in the treatment of malignant melanoma. Hautarzt 66(7):545–548. doi:10.1007/s00105-014-3567-8
10. Grimaldi AM, Simeone E, Giannarelli D et al (2014) Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology 3:e28780. doi:10.4161/onci.28780 eCollection 2014
11. Mali B, Jarm T, Snoj M, Sersa G, Miklavcic D (2013) Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis. Eur J Surg Oncol 39(1):4–16. doi:10.1016/j.ejso.2012.08.016
12. Brizio M, Fava P, Astrua C, Cavaliere G, Savoia P (2015) Complete regression of melanoma skin metastases after electrochemotherapy plus ipilimumab treatment: an unusual clinical presentation. Eur J Dermatol 25(3):271–272. doi:10.1684/ejd.2015.2522
13. Sersa G, Teissie J, Cemazar M, Signori E, Kamensek U, Marshall G, Miklavcic D (2015) Electrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransfer. Cancer Immunol Immunother 64(10):1315–1327. doi:10.1007/s00262-015-1724-2
14. Queirolo P, Marincola F, Spagnolo F (2014) Electrochemotherapy for the management of melanoma skin metastasis: a review of the literature and possible combinations with immunotherapy. Arch Dermatol Res 306(6):521–526. doi:10.1007/s00403-014-1462-x
15. Mozzillo N, Simeone E, Benedetto L et al (2015) Assessing a novel immuno-oncology-based combination therapy: ipilimumab plus electrochemotherapy. Oncoimmunology 4(6):e1008842. doi:10.1080/2162402X.2015.1008842
16. Marty M, Sersa G, Garbay JR et al (2006) Electrochemotherapy—an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. EJC Suppl 4(11):3–13. doi:10.1016/j.ejcsup.2006.08.002
17. Campana LG, Clover AJ, Valpione S et al (2016) Recommendations for improving the quality of reporting clinical electrochemotherapy studies based on qualitative systematic review. Radiol Oncol 50(1):1–13. doi:10.1515/raon-2016-0006
18. Balch CM, Gershenwald JE, Soong SJ et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199–6206. doi:10.1200/JCO.2009.23.4799
19. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. doi:10.1016/j.ejca.2008.10.026
20. Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17(4):343–346
21. Queirolo P, Spagnolo F, Ascierto PA et al (2014) Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neurooncol 118(1):109–116. doi:10.1007/s11060-014-1400-y
22. Postow MA, Chesney J, Pavlick AC et al (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372(21):2006–2017. doi:10.1056/NEJMoa1414428
23. Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23–34. doi:10.1056/NEJMoa1504030
24. Larkin J, Hodi FS, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(13):1270–1271. doi:10.1056/NEJMc1509660
25. Testori A, Rossi CR, Tosti G (2012) Utility of electrochemotherapy in melanoma treatment. Curr Opin Oncol 24(2):155–161. doi:10.1097/CCO.0b013e32834fcaa8